MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Libidon Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Libidon (Prostate Cytomax A-16) is an oral Khavinson peptide bioregulator: a complex of short peptides (under ~5,000 Da) extracted from bovine prostate tissue, supplied as 10 mg capsules [4][8]. Rather than acting hormonally, its ultrashort peptides are proposed to enter cell nuclei and bind promoter DNA, tuning tissue-specific gene expression and protein synthesis in prostate and immune cells (PMID 34834147) [1][2]. The standard course is 20 mg/day (one 10 mg capsule twice daily) for 30 days, with a 10 mg/day starter option and a 10-day maintenance pulse every 3-6 months [4]. An institute observation of 48 men reported less pain, frequency, and nocturia in prostatitis and BPH, echoing Russian urology with related prostate peptides such as Prostatilen and Vitaprost [5][6][7]. It is taken orally; the subcutaneous reconstitution figures here are an educational measurement reference only. Libidon is not FDA- or EMA-approved and is sold as a supplement or research material.
Reconstitute: Add 1 mL bacteriostatic water → 20 mg/mL concentration.
Typical dose: 10-20 mg/day orally (10 mg/capsule); 10-30 day course
Easy measuring: At 20 mg/mL, 1 unit = 0.01 mL = 0.2 mg (200 mcg) on a U-100 insulin syringe.
Storage: Capsules: store at room temperature, protected from light and moisture. Educational research-vial model: lyophilized powder kept frozen at −20 °C; once reconstituted, refrigerate at 2-8 °C and use within about four weeks.
Half-life: Not formally established in humans; constituent ultrashort peptides clear within minutes, so effects are framed as cumulative over a 10-30 day course rather than a blood-level peak.
Route: Oral capsules (10 mg) or sublingual drops, taken once to twice daily; modeled here as a subcutaneous reconstitution reference for measurement only, not a recommended route.
Status: Not FDA- or EMA-approved; bovine prostate peptide bioregulator sold as a dietary supplement / research material. Educational content, not medical advice.
About Libidon
Libidon, also sold as Prostate Cytomax A-16, is an orally administered Khavinson peptide bioregulator: a concentrated complex of short peptides (molecular weight under ~5,000 Da) extracted from bovine prostate tissue and packaged in 10 mg capsules [4][8]. It belongs to the "cytomax" class of tissue extracts, which carry the full spectrum of organ-specific peptide fractions rather than a single synthetic sequence, and it is marketed for men's prostate and urogenital support, not as an approved medicine.\n\nClinically, and in every published protocol, Libidon is taken by mouth, so the standard Libidon dosage is expressed in capsules: most sources describe 20 mg per day (one 10 mg capsule twice daily, with breakfast and dinner) for a 30-day course, with a conservative 10 mg/day starting option and a 10-day maintenance course repeated every 3-6 months [4]. The subcutaneous vial-and-bacteriostatic-water figures below are an educational reconstitution reference only; they let you map the oral milligram doses onto a familiar injection model and are not the real-world route.\n\nThis guide models a 20 mg research vial reconstituted with 1.0 mL of bacteriostatic water (20 mg/mL, i.e. 200 mcg per insulin-syringe unit), so 10 mg measures 50 units (0.50 mL) and the full 20 mg daily dose measures 100 units (1.00 mL) on a U-100 syringe.\n\nFrequency: Oral capsules are taken once or twice daily across a 10-30 day course; the educational injection model shown here is once daily. Libidon is not FDA- or EMA-approved and is presented for educational purposes only.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 1.0 mL of bacteriostatic water into a sterile syringe; added to a 20 mg research vial this yields a 20 mg/mL solution, about 200 mcg per insulin-syringe unit.
Inject the water slowly down the inner wall of the vial; do not aim the stream directly at the powder, and avoid vigorous shaking that could froth or denature the peptides.
Swirl or roll the vial gently until the solution is completely clear; the result is 20 mg/mL, so 10 mg measures 50 units (0.50 mL) and 20 mg measures 100 units (1.00 mL).
Store the reconstituted vial refrigerated at 2-8 °C and use within about four weeks; draw the units for your phase (10 mg = 50 units / 0.50 mL, 20 mg = 100 units / 1.00 mL).
Educational note: Libidon is clinically taken ORALLY as capsules, so these subcutaneous figures are a measurement reference only. For the modeled injection, swab the site, inject slowly into subcutaneous tissue, and rotate sites.
Interactive Libidon Syringe Calculator
Currently visualizing the 20 mg vial reconstituted with 1 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 20mg dry powder in 1mL water yields 20.00 mg/mL. To evaluate a 250mcg dose, pull to 1.3 units (1 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Starter / lighter course (10 mg/day, one 10 mg capsule equivalent) | 10000 mcg (10 mg) | 50 units (0.50 mL) |
| Standard 30-day intensive course (20 mg/day, two 10 mg capsules) | 20000 mcg (20 mg) | 100 units (1.00 mL) |
| Maintenance pulse (20 mg/day for 10 days, repeated every 3-6 months) | 20000 mcg (20 mg) | 100 units (1.00 mL) |
Administration guidelines: Refer to guidelines | 1 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 20 mg vial.
Peptide Vials (Libidon, 20 mg each):
- checkAt the standard 20 mg/day, the injection model uses one 20 mg vial per day (7 vials/week)
- checkA realistic single 30-day course at 20 mg/day ≈ 30 vials (600 mg total)
- checkIllustrative continuous use: 8 weeks ≈ 56 vials, 12 weeks ≈ 84 vials, 16 weeks ≈ 112 vials — in practice Libidon is taken as 10-30 day courses, not continuously
Insulin Syringes (U-100):
- checkOnce-daily dosing: 7 syringes per week
- check8 weeks ≈ 56 syringes; 12 weeks ≈ 84 syringes; 16 weeks ≈ 112 syringes
- checkA 30-day course ≈ 30 syringes; the 20 mg dose fits one syringe (100 units / 1.00 mL)
Bacteriostatic Water (30 mL bottles): Use 1 mL per 20 mg vial for reconstitution.
- checkA 30-day course ≈ 30 mL ≈ 1 bottle
- check8 weeks ≈ 56 mL ≈ 2 bottles; 12 weeks ≈ 84 mL ≈ 3 bottles
- check16 weeks ≈ 112 mL ≈ 4 bottles
Alcohol Swabs:
- check1-2 swabs per dose (vial top + injection site)
- check30-day course ≈ 30-60 swabs; 8 weeks ≈ 56-112 swabs
- check12 weeks ≈ 84-168 swabs; 16 weeks ≈ 112-224 swabs — keep extras for re-swabbing the multi-use vial
Mechanism of Action (MOA)
Libidon is a "cytomax" peptide bioregulator: a complex of low-molecular-weight peptides (under ~5,000 Da) extracted from the prostate glands of young cattle, standardized to 10 mg of peptide complex A-16 per capsule [4]. Unlike a single synthetic sequence, a cytomax carries the full spectrum of tissue-specific peptide fractions native to the source organ. Analytical characterization of bovine prostate extracts has identified a peptidome of regulatory fragments, including a chemokine MCP-1-derived peptide shown in vitro to suppress monocyte migration and platelet aggregation, providing a molecular rationale for the anti-inflammatory and antiplatelet behavior attributed to prostate peptide preparations [8].\n\nThe proposed mechanism is epigenetic rather than hormonal. In the Khavinson framework, ultrashort peptides of two to seven residues are small enough to penetrate the cell membrane and nuclear envelope, enter the nucleus and nucleolus, and bind specific promoter regions of double-stranded DNA through steric and electrostatic complementarity. This interaction is hypothesized to alter DNA methylation status and chromatin accessibility, switching tissue-specific genes on or off and thereby tuning protein synthesis in prostate and immune cells [1]. An independent review of peptides as epigenetic modulators corroborates that Khavinson di-, tri- and tetrapeptides can interact with promoter DNA and act as DNA-methylation modulators that initiate transcription, although most of this evidence is in vitro and in cell culture rather than from human prostate trials [2].\n\nDownstream, the prostate peptide family (Prostatilen, Vitaprost and related cytomedins) has been described in Russian urology as anti-inflammatory and immunomodulating, improving prostatic microcirculation and normalizing hemostasis, which is offered as one pathway behind symptomatic improvement in chronic prostatitis [5][6][7]. Broader bioregulator research positions these peptides as geroprotectors that, in long-term animal studies, raised lifespan and reduced tumor incidence, framing organ-specific cytomaxes like Libidon as tools intended to restore age-related decline in target-tissue function [3].\n\nPharmacokinetics in humans are not formally established. The constituent ultrashort peptides are expected to be hydrolyzed in plasma within minutes, so no meaningful "half-life" governs dosing; instead, effects are framed as cumulative across a 10-30 day course rather than tied to a peak blood level, which is why protocols are course-based and periodically repeated [3][4]. Oral and sublingual capsules are the real delivery routes; the subcutaneous reconstitution scheme on this page is an educational measurement convention used across this site, not a validated or recommended way to administer a bovine tissue extract. Libidon is not approved by the FDA or EMA, and the human evidence base is limited, short-term, and largely generated at the originating institute [4].
Clinical Trial Efficacy Highlights
- starThe originating institute's clinical study report on Libidon describes 48 men aged 38-65 (28 with chronic prostatitis, 20 with benign prostatic hyperplasia) given one 10 mg capsule twice daily for 30 days, versus 22 controls; among prostatitis patients it reported pain elimination in ~64%, restored sexual function in ~44%, and resolution of frequent urination in ~87.5%, with improved urinary flow and less nocturia in BPH patients [4]. This is an institute-internal, non-randomized observation rather than an independently replicated controlled trial, so the results should be read cautiously.
- starKhavinson and colleagues' systematic review in Molecules (2021) summarizes the proposed mechanism: short peptides of 2-7 amino acids can penetrate into cell nuclei and nucleoli, interact with histones and DNA, and regulate gene expression and DNA methylation in a tissue-specific manner, the conceptual basis for cytomax preparations such as Libidon [1].
- starAn independent review of peptides as epigenetic modulators (Janssens et al., Clinical Epigenetics 2019) corroborates that Khavinson di-, tri- and tetrapeptides interact with promoter DNA and can act as DNA-methylation modulators that initiate transcription, providing external mechanistic support, though the evidence is in vitro and not specific to Libidon or to human prostate endpoints [2].
- starDecades of Russian urology with the parent bovine prostate peptide Prostatilen report anti-inflammatory and immunomodulating activity; one clinical and experimental study found that normalization of hemostasis is one factor in its therapeutic efficacy in chronic prostatitis [5].
- starA clinical report on the polypeptide preparation Prostatilen in patients with complicated prostatitis describes symptomatic and functional improvement, supporting the broader prostate-peptide class to which Libidon belongs while noting these are different formulations [6].
- starThe closest controlled evidence for an oral prostate-peptide product comes from a study of oral Vitaprost for prevention of exacerbations of chronic abacterial prostatitis, which reported that the tablets roughly halved the probability of exacerbation; this supports biological plausibility for oral prostate peptides but concerns a separate registered product, not Libidon [7].
- starPeptidomic characterization of cattle prostate extract (Savel'ev et al., Pharmaceutical Chemistry Journal 2024) identified an MCP-1-fragment peptide that suppressed monocytic-cell migration and platelet aggregation in vitro, offering a concrete molecular basis for the anti-inflammatory and antiplatelet effects attributed to prostate extracts like Libidon [8].
- starLong-term experimental work on peptide bioregulators as a class (Khavinson et al., Advances in Gerontology 2012) reports increased lifespan and reduced tumor incidence in animals, framing organ-specific cytomaxes as geroprotectors; this is supportive background rather than direct clinical proof for prostate outcomes in men [3].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningManufacturer and institute sources report that Libidon was well tolerated with no adverse effects, complications, or dependence over the 30-day course [4]; however, this rests on short-term, institute-internal observation, so an absence of side effects has not been confirmed by independent randomized trials.
- warningBecause the product is a bovine tissue extract, there is a theoretical risk of hypersensitivity or allergic reaction; it should be avoided by anyone with known allergy to beef or bovine proteins, and animal-tissue sourcing carries general (if low) prion/contaminant considerations addressed through manufacturing controls.
- warningLibidon is not a substitute for medical evaluation of prostate symptoms: lower urinary tract symptoms, an elevated PSA, urinary retention, or new pelvic pain require physician work-up to exclude prostate cancer and other pathology, and self-treating can delay diagnosis.
- warningRoute caveat: actually injecting a bovine tissue extract, as the educational model on this page depicts, is not how the product is used and could cause injection-site reactions, infection, or sterility problems; the validated route is oral (capsules) or sublingual.
- warningDrug interactions are largely unstudied; if the antiplatelet activity seen in prostate-extract peptides is clinically relevant [8], there is a theoretical additive effect with anticoagulant or antiplatelet medication, so caution is warranted in those patients.
- warningAs a product marketed for the prostate, men with prostate cancer, on androgen-deprivation therapy, or under active urological treatment should consult their clinician before use, since effects on hormone-sensitive tissue are not characterized.
- warningSupplement-grade quality varies between vendors; there is no standardized potency assay or pharmacopeial monograph for Libidon, so actual peptide content, purity, and sterility are not guaranteed.
- warningRegulatory/research status: Libidon is NOT approved by the FDA or EMA as a drug. It is sold as a dietary supplement or research material, human safety data are limited to short courses, and this page is educational content, not medical advice.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Libidon dosage?expand_more
The most commonly cited Libidon dosage is 20 mg per day, taken as one 10 mg capsule twice daily with meals (morning and evening), for a 30-day course. A lighter 10 mg/day option exists, and a maintenance protocol of 20 mg/day for 10 days is often repeated every 3-6 months [4]. Libidon is dosed by mouth as capsules; the subcutaneous vial figures on this page (20 mg vial in 1.0 mL of bacteriostatic water, so 10 mg = 50 units and 20 mg = 100 units on a U-100 syringe) are an educational measurement reference only, not a recommended route.
Is Libidon FDA approved?expand_more
No. Libidon is not approved by the FDA or the EMA for any medical indication. It is a bovine prostate peptide bioregulator (cytomax A-16) sold as a dietary supplement or research material, and its clinical evidence is limited, short-term, and largely generated at the originating St. Petersburg institute [4]. It is not a substitute for evaluation and treatment of prostate conditions by a licensed clinician, and this page is educational, not medical advice.
How is Libidon reconstituted in the injection model on this page?expand_more
Clinically Libidon is swallowed, so no reconstitution is needed in real use. For the educational subcutaneous model, a 20 mg research vial is mixed with 1.0 mL of bacteriostatic water to give 20 mg/mL: draw the water slowly down the vial wall, swirl gently until clear, and refrigerate. At that concentration 10 mg measures 50 units (0.50 mL) and the full 20 mg daily dose measures 100 units (1.00 mL) on a U-100 insulin syringe. Injecting a bovine tissue extract is not how the product is used and is shown only to map the oral milligram doses onto a familiar scale.
What is the half-life of Libidon?expand_more
There is no formally established human half-life for Libidon. It is a mixture of ultrashort peptides that are expected to be broken down in plasma within minutes, so dosing is not driven by a blood-level peak. In the Khavinson bioregulator model, effects are framed as cumulative across a 10-30 day course rather than tied to a single dose, which is why protocols are course-based and periodically repeated every few months [3][4].
Can Libidon be stacked with other Khavinson peptide bioregulators?expand_more
In anti-aging practice Libidon is sometimes combined with other organ-specific cytomaxes (for example pineal or testis bioregulators), the rationale being that each targets a different tissue's gene expression. There is no controlled human data validating any such combination, and if the antiplatelet activity reported for prostate-extract peptides is relevant, there is a theoretical additive effect with blood thinners [8]. Treat any stack as experimental and discuss it with a clinician, especially if you take anticoagulants or have a prostate diagnosis.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Libidon, plus the universal dosing calculator.
Academic References & Study Citations
Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. View Scientific Paper →
Janssens Y, Wynendaele E, Vanden Berghe W, De Spiegeleer B. Peptides as epigenetic modulators: therapeutic implications. Clin Epigenetics. 2019;11(1):101. View Scientific Paper →
Khavinson VKh, Kuznik BI, Ryzhak GA. [Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studies]. Adv Gerontol (Uspekhi Gerontologii). 2012;25(4):696-708. (Russian) View Scientific Paper →
Report on the results of a clinical study of peptide bioregulator Libidon. Medical Center, St. Petersburg Institute of Bioregulation and Gerontology (V. Khavinson), 2011 (48 patients with chronic prostatitis / BPH; institute-affiliated report). View Scientific Paper →
Kuznik BI, et al. [The effect of prostatilen on the hemostatic indices in chronic prostatitis (a clinical and experimental study)]. Urol Nefrol (Mosk). 1997;(3):38-41. (Russian) View Scientific Paper →
[Polypeptide prostatilen in the treatment of patients with complicated prostatitis]. Urologiia. 2004;(6):26-29. (Russian) View Scientific Paper →
[Administration of oral vitaprost for prevention of exacerbations of chronic abacterial prostatitis]. Urologiia. 2009;(1):54-58. (Russian) View Scientific Paper →
Savel'ev SA, Mittenberg AG, Aref'eva TI, et al. Peptide Composition and Identification of a Peptide with Anti-Inflammatory and Antiplatelet Properties in Cattle Prostate Extract. Pharm Chem J. 2024;58:35-43. View Scientific Paper →